On May 28, 2019 Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, reported that Elisabet de los Pinos, Ph.D., Chief Executive Officer of Aura, will present a company overview at the Jefferies 2019 Global Healthcare Conference on Tuesday, June 4, 2019, at 2:00 p.m. Eastern Time in New York, NY (Press release, Aura Biosciences, MAY 28, 2019, View Source [SID1234536596]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On May 28, 2019 Synaffix B.V., a Dutch biotechnology company focused on the advancement of its clinical-stage antibody-drug conjugate (ADC) technology for the development of best-in-class ADCs, reported that ADC Therapeutics has triggered a third target-specific license under its existing Commercial License Agreement dated October 2016 (Press release, Synaffix, MAY 28, 2019, View Source [SID1234536595]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This license provides ADC Therapeutics with the rights to Synaffix’s proprietary GlycoConnect site-specific antibody-drug conjugation and HydraSpace polar spacer technologies to develop and commercialize a third product candidate against a specific target.

Under the terms of the agreement, Synaffix is eligible to receive upfront, milestone and royalty payments on a per-target basis. Further financial details were not disclosed.

Peter van de Sande, CEO of Synaffix said:

"We are very pleased with our collaboration, the rapid progress made by ADC Therapeutics and the successive expansion to date. This third target-specific license taken out by ADC Therapeutics provides further validation of our ADC technology. Since we reached our license agreement, Synaffix’s GlycoConnect and HydraSpace technologies have continued to demonstrate their ability to generate exceptional ADC product candidates in terms of therapeutic index."

"2019 has been a tremendous year so far for Synaffix. The first ADC Therapeutics product candidate generated using our technology reached the clinic in January 2019 and we have signed additional commercial license agreements with other partners – Mersana Therapeutics, USA and Shanghai Miracogen, China. We look forward to continuing our close collaboration with our license partners, enabling their best-in-class ADCs and expanding our list of collaborations further."

On May 28, 2019 OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a biotechnology company focused on designing, developing and commercializing innovative immunotherapies and proprietary medical approaches to stimulate and guide an anti-tumor immune response for the treatment of cancer, reported the closing of its previously announced underwritten public offering (Press release, OncoSec Medical, MAY 28, 2019, View Source [SID1234536594]). The gross proceeds from the offering were approximately $11 million, before deducting underwriting discounts and commissions and estimated offering expenses paid by OncoSec.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Alliance Global Partners acted as lead book-running manager for the offering. Maxim Group LLC acted as co-manager and Roth Capital Partners, LLC and ThinkEquity, a division of Fordham Financial Management, Inc., acted as financial advisors for this offering.

With the closing of this transaction, OncoSec’s current pro forma unaudited cash, cash equivalents and investment balance exceed $30 million. The proceeds from this offering are expected to fund OncoSec’s clinical research and development activities, to provide working capital and to support general corporate purposes for at least the next 12 months.

The Company also announced the termination of its at-the-market (ATM) agreement with Cantor Fitzgerald and its existing equity facility with Aspire Capital.

The offering was made pursuant to a shelf registration statement on Form S-3 that was filed with the Securities Exchange Commission (SEC) on August 9, 2016 and declared effective by the SEC on August 25, 2016. The final prospectus supplement for the offering is available on the SEC’s website located at View Source Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained from A.G.P./Alliance Global Partners, 590 Madison Avenue, 36th Floor, New York, NY 10022 or via telephone at 212-624-2006 or email: [email protected].

On May 28, 2019 Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, reported that it will present data from the Phase 1/2 study of its proprietary, selective cortisol modulator, relacorilant, in combination with nab-paclitaxel (Abraxane) in patients with solid tumors, at the 2019 annual meeting of the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) in Chicago, Illinois (May 31 – June 4) (Press release, Corcept Therapeutics, MAY 28, 2019, https://ir.corcept.com/news-releases/news-release-details/corcept-therapeutics-present-data-phase-12-trial-relacorilant [SID1234536593]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Our Phase 1/2 trial of relacorilant in combination with nab-paclitaxel has been productive," said Andreas Grauer, MD, Corcept’s Chief Medical Officer. "Encouraging results in patients with platinum-resistant ovarian cancer prompted us, after consultation with our investigators, to initiate a 180-patient, controlled Phase 2 trial of relacorilant plus nab-paclitaxel in that indication earlier this year. We look forward to sharing additional data in patients with a variety of solid tumors."

Monday, June 3rd
Relacorilant (RELA) with nab-paclitaxel (NP): Safety and
activity in patients with pancreatic ductal adenocarcinoma
(PDAC) and ovarian cancer (OvCA)

P. Munster; S. Shepard Gastrointestinal (Noncolorectal) Cancer
Poster Board: #235
Time: 8:00 – 11:00 am
Location: Hall A

Selective and nonselective GR antagonists in combination
with chemotherapy in ovarian cancer PDX models

J. Veneris; G. Fleming Gynecologic Cancer
Abstract No: e17039

About Relacorilant

Relacorilant is a non-steroidal, selective modulator of the glucocorticoid receptor, one of the two receptors to which cortisol binds. Relacorilant does not bind to the body’s other hormone receptors, including the progesterone receptor. Corcept is studying relacorilant as a potential treatment for a variety of serious disorders. Current trials include a 180-patient, controlled Phase 2 trial of relacorilant combined with nab-paclitaxel in patients with platinum-resistant ovarian cancer and a Phase 3 trial of relacorilant as monotherapy for patients with Cushing’s syndrome. Relacorilant is proprietary to Corcept and is protected by composition of matter and method of use patents through 2037. Relacorilant has received orphan designation in the United States for the treatment of both Cushing’s syndrome and pancreatic cancer.

On May 27, 2019 Affibody AB ("Affibody"), a clinical stage biopharmaceutical company, reported an agreement with 3P Biopharmaceuticals ("3P") covering process development and GMP manufacturing of Affibody’s ABY-035 drug.
Affibody secures production capacity for ABY-035 (Press release, Affibody, MAY 27, 2019, View Source [SID1234575708]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

An important next step in the advancement of ABY-035 to late stage clinical development.
"Ensuring large scale high quality production of our ABY-035 drug is a natural next step in our evolution as a company with the ambition to have development, manufacturing, and commercialization expertise", said David Bejker, CEO of Affibody. "The work we have initiated together with 3P is important for us and we look forward to working with 3P."

According to the agreement, 3P is responsible for transferring the process developed by Affibody to its facilities prior to execution of the first GMP manufacturing batches. 3P will also perform the process characterization and the process validation before entering the commercial batch manufacturing stage.

"We are very pleased to be working with Affibody on this project and to create a strong long-term partnership with them. We are sure that this is a mutually beneficial agreement." says Dámaso Molero, General Manager at 3P Biopharmaceuticals.